Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Mar;26(3):537-42.
doi: 10.1681/ASN.2013111233. Epub 2014 Oct 16.

ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease

Affiliations

ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease

Michael J Kemna et al. J Am Soc Nephrol. 2015 Mar.

Abstract

The value of measuring ANCA during follow-up to predict a relapse is controversial. On the basis of recently obtained pathophysiologic insights, we postulated that measuring ANCA is useful in patients with renal involvement but is less valuable in patients with nonrenal disease. One hundred sixty-six consecutive patients with ANCA-associated vasculitis, positive for either proteinase 3 (PR3)-ANCA or myeloperoxidase (MPO)-ANCA, were included in our study, followed at regular intervals, and tested for PR3-ANCA and MPO-ANCA. In this cohort, 104 patients had renal involvement (72 with PR3-ANCA, 32 with MPO-ANCA) and 62 patients had nonrenal disease (36 with PR3-ANCA, 26 with MPO-ANCA). During an average (±SD) follow-up of 49±33 months and 18±14 ANCA measurements, 89 ANCA rises and 74 relapses were recorded. ANCA rises correlated with relapses in patients who presented with renal involvement (hazard ratio [HR], 11.09; 95% confidence interval [95% CI], 5.01 to 24.55), but in comparison, associated only weakly with relapses in patients who presented with nonrenal disease (HR, 2.79; 95% CI, 1.30 to 5.98). In conclusion, longitudinal ANCA measurements may be useful in patients with renal involvement but is less valuable in patients with nonrenal disease.

Keywords: ANCA; GN; vasculitis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flowchart of the included patients. As shown, patients who become ANCA negative during follow-up do not experience a major relapse if an ANCA rise has not occurred.
Figure 2.
Figure 2.
The predictive value of an ANCA rise as determined by the antigen-specific solid-phase ANCA method in the entire cohort and subgroups of patients with AAV. A differentiation is made in renal involvement, sampling interval (<4 versus ≥4 per year), ANCA pattern (persistently positive or nonpersistently positive), and ANCA serotype (MPO-ANCA versus PR3-ANCA). HRs are shown with 95% CIs. The area up to a HR of 1 marks the border of significance.

Comment in

References

    1. Wilde B, van Paassen P, Witzke O, Tervaert JWC: New pathophysiological insights and treatment of ANCA-associated vasculitis. Kidney Int 79: 599–612, 2011 - PubMed
    1. Tervaert JWC, van der Woude FJ, Fauci AS, Ambrus JL, Velosa J, Keane WF, Meijer S, van der Giessen M, The TH, van der Hem GK, Kallenberg GM: Association between active Wegener’s granulomatosis and anticytoplasmic antibodies. Arch Intern Med 149: 2461–2465, 1989 - PubMed
    1. Tervaert JWC, Damoiseaux J: Antineutrophil cytoplasmic autoantibodies: How are they detected and what is their use for diagnosis, classification and follow-up? Clin Rev Allergy Immunol 43: 211–219, 2012 - PubMed
    1. Birck R, Schmitt WH, Kaelsch IA, van der Woude FJ: Serial ANCA determinations for monitoring disease activity in patients with ANCA-associated vasculitis: Systematic review. Am J Kidney Dis 47: 15–23, 2006 - PubMed
    1. Tomasson G, Grayson PC, Mahr AD, Lavalley M, Merkel PA: Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis—A meta-analysis. Rheumatology (Oxford) 51: 100–109, 2012 - PMC - PubMed

Substances